Artiva Biotherapeutics, Inc. (ARTV)

Every figure this model derived for ARTV, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 1,678,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 349,394,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 352,276,000 AssetsCurrent 2026-06-30
current liabilities 14,581,000 LiabilitiesCurrent 2026-06-30
equity 347,502,000 StockholdersEquity 2026-06-30
ocf -75,232,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 0 Revenues 2025-12-31
sbc 6,678,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ARTV on one particular measure came for.

RatioValue
current ratio24.16
current ratio reported24.16
dilution pct117.23
revenue growth-100.0
revenue growth per share-100.0

What to be careful about

What this model itself distrusts about ARTV's figures. Written by the derivation as it ran, not added afterwards.